Initial Diagnosis and Treatment of Low-Risk Gestational Trophoblastic Neoplasia.

Hematol Oncol Clin North Am

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA; Harvard Medical School, Boston, Boston, MA 02115, USA.

Published: December 2024

Gestational trophoblastic neoplasia (GTN) is a rare form of cancer that is treated according to the World Health Organization (WHO) risk score, which predicts responsiveness to single-agent chemotherapy. Patients with WHO risk scores ≤6 have low-risk GTN, for which cure rates near 100%. Most women with low-risk GTN will respond to single-agent chemotherapy, which is given with either methotrexate or dactinomycin, and allows women to retain their fertility. This article also discusses less common treatment paradigms including second dilation and curettage and hysterectomy, as well as the emerging role of immunotherapy in managing low-risk GTN.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2024.07.005DOI Listing

Publication Analysis

Top Keywords

low-risk gtn
12
gestational trophoblastic
8
trophoblastic neoplasia
8
single-agent chemotherapy
8
initial diagnosis
4
diagnosis treatment
4
low-risk
4
treatment low-risk
4
low-risk gestational
4
neoplasia gestational
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!